In premenopausal women with HR‐positive, HER2‐negative breast cancer, regardless of the recurrence score, ovarian function suppression (OFS) combined with tamoxifen or an aromatase inhibitor (AI) improves response to preoperative endocrine therapy compared with endocrine monotherapy. This evidence concerns the gene ERBB2 and breast cancer.